Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 12
1966 39
1967 46
1968 58
1969 71
1970 52
1971 73
1972 59
1973 83
1974 85
1975 107
1976 86
1977 107
1978 91
1979 91
1980 75
1981 70
1982 103
1983 108
1984 131
1985 126
1986 126
1987 112
1988 107
1989 127
1990 115
1991 105
1992 116
1993 106
1994 108
1995 115
1996 129
1997 116
1998 120
1999 111
2000 149
2001 106
2002 121
2003 132
2004 137
2005 131
2006 182
2007 183
2008 165
2009 169
2010 190
2011 202
2012 223
2013 184
2014 215
2015 196
2016 202
2017 169
2018 147
2019 159
2020 143
2021 108
2022 102
2023 80
2024 94
2025 83
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,696 results

Results by year

Filters applied: . Clear all
Page 1
Multiple myeloma.
Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, Manier S, Mohty M. Malard F, et al. Nat Rev Dis Primers. 2024 Jun 27;10(1):45. doi: 10.1038/s41572-024-00529-7. Nat Rev Dis Primers. 2024. PMID: 38937492 Review.
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Ann Surg Oncol. 2024 Aug;31(8):5340-5351. doi: 10.1245/s10434-024-15293-x. Epub 2024 May 4. Ann Surg Oncol. 2024. PMID: 38704501 Free PMC article. Clinical Trial.
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodríguez-Otero P, Leleu X, Richardson PG. Nadeem O, et al. Drugs Today (Barc). 2022 Aug;58(8):407-423. doi: 10.1358/dot.2022.58.8.3367680. Drugs Today (Barc). 2022. PMID: 35983927 Review.
Optimizing high dose melphalan.
Shah G, Giralt S, Dahi P. Shah G, et al. Blood Rev. 2024 Mar;64:101162. doi: 10.1016/j.blre.2023.101162. Epub 2023 Dec 10. Blood Rev. 2024. PMID: 38097487 Review.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Richardson PG, et al. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660812 Free PMC article. Clinical Trial.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
Lahuerta JJ, San-Miguel J, Jiménez-Ubieto A, Alonso R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernández Guijarro M, Tamayo RR, Rocafiguera AO, Blanchard MJ, Carrillo Cruz E, Martínez-Martínez R, Bargay J, Sureda Balari A, Rubia J, Hernández García MT, Cabañas V, Montero FC, Bernal LP, Montes YG, Martínez-Lopez J, Rodriguez-Otero P, Krisnik I, Arguiñano JM, Gonzalez García ME, Ocio EM, Cruz J, Mateos MV, Rosiñol L, Bladé J. Lahuerta JJ, et al. Blood. 2025 Oct 9;146(15):1747-1758. doi: 10.1182/blood.2025028313. Blood. 2025. PMID: 40499010 Clinical Trial.
6,696 results